Lupus-Like Anticoagulants, Modulation of the Protein C Pathway and Thrombosis

Key words

Lupus-like anticoagulants - Thrombosis - Phospholipids - Protein C pathway - Thrombogenic endothelium

• References

• 1 Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemostasis Thromb 1982; 6: 263-285
• 2 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostasis Thromb 1972; 1: 75-95
• 3 Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622
• 4 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
• 5 Cohen AJ, Philipps TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 175-180
• 6 Gastineau DA, Kazmier FJ, Nichols WL, Bowie E JW. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Amer J Hematol 1985; 19: 265-275
• 7 Lechner K, Pabinger-Fashing I. Lupus anticoagulants and thrombosis. Haemostasis 1985; 15: 254-262
• 8 Hougie C. Circulating anticoagulants. In: Recent Advances in Blood Coagulation. Poller L. (Ed) Churchill Livingstone. Edinburgh: 1985 4. 63-90
• 9 Vermylen J, Blockmans D, Spitz B, Deckmyn H. Thrombosis and immune disorders. Clin Haematol 1986; 15: 393-412
• 10 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Ann Intern Med 1984; 144: 510-515
• 11 Zwaal R FA, Hemker HC. Blood cell membranes and haemostasis. Haemostasis 1982; 11: 12-39
• 12 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin MX, coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
• 13 Howard MA, Firkin BG. Investigations of the lupus-like inhibitor by-passing activity of platelets. Thromb Haemostas 1983; 50: 775-779
• 14 Dahlback B, Nilsson IM, Frohm B. Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 1983; 62: 218-225
• 15 Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time. The central role of phosphatidylserine. Thromb Haemostas 1984; 52: 172-175
• 16 Triplett DA, Brandt JT, Mass RL. The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 1985; 109: 946-951
• 17 Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CP S, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chern 1986; 261: 9672-9677
• 18 Alving CR. Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 1986; 40: 303-314
• 19 Harris EN, Gharavi EA, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes G VR. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; II: 1211-1214
• 20 Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-156
• 21 Hamsten A, Norberg R, Bjorkholm M, De Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1986; I: 113-116
• 22 Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. In: Molecular Biology of the Cell. Garland Publishing; New York: 1983
• 23 Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41: 8-15
• 24 Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: Detection of immunoglobulin interfering with prostacyclin production. Lancet 1981; 1: 244-246
• 25 Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979; 94: 312-323
• 26 Esmon CT. Regulation of protein C activation by components of the endothelial cell surface. In: Vascular endothelium in hemostasis and thrombosis. Gimbrone MA. (Ed). Churchill Livingstone; Edinburgh: 1986. p 99-119
• 27 Stenflo J. Structure and function of protein C. Semin Thromb Hemostasis 1984; 10: 109-121
• 28 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor V_a inactivation. J Biol Chem 1981; 256: 11128-11131
• 29 Griffin JH. Clinical studies of protein C. Semin Thromb Hemostasis 1984; 10: 162-166
• 30 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528
• 31 Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62 5 Suppl 1 299a (Abstr)
• 32 Cariou R, Tobelem G, Caen J. L’anticoagulant circulant de type lupus, facteur de risque thrombotique par inhibition de 1’activation de la proteine C. C R Acad Sci Ser III-Vie 1986; 303: 113-118
• 33 Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J 1986; 238: 151-157
• 34 Galvin JB, Kurosawa S, Moore K, Esmon CT, Esmon NL. Reconstitution of rabbit thrombomodulin into phospholipid vesicles. J Biol Chem 1987; 262: 2199-2205
• 35 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemostas 1986; 55: 309-313
• 36 Friedman KD, Marlar RA, Gill JC, Endres-Brooks J, Montgomery RR. Protein S deficiency in patients with the lupus anticoagulant. Blood 1986; 68 5 Suppl 1 333 (Abstr)
• 37 Maruyama I, Majerus PW. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 cancer cells. J Biol Chem 198 260: 15432-15438
• 38 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases anti-activator activity. Proc Natl Acad Sci USA; 1985; 82: 1121-1125
• 39 Van Hinsberg V WM, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
• 40 Cazenave JP, Klein-Soyer C, Beretz A. The vascular endothelium. An important site of blood-tissue exchanges. Inter Angiol 1984; 3: 27-32
• 41 Nawroth PP, Stern DM. Endothelial cells as active participants in procoagulant reactions. In: Vascular endothelium in hemostasis and thrombosis. Gimbrone MA. (Ed) Churchill Livingstone; Edinburgh: 1986. p 14-39
• 42 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-130
• 43 Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363-1375
• 44 Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-3464
• 45 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
• 46 Nawroth PP, Cornelson S, Stern DM. Tumor necrosis factor upregulates factor IX/IXa binding sites and factor IXa-VIII-mediated factor Xa formation on endothelium. Circulation 1986; 74: 11-233 (Abstr)
• 47 Nawroth PP, Handley DA, Stern DM. Tumor necrosis factor-induced tumor killing involves coagulation. Circulation 1986; 11-233 (Abstr)